BBLG
Bone Biologics·NASDAQ
--
--(--)
--
--(--)
BBLG fundamentals
During Q4 2025, Bone Biologics (BBLG) reported revenue of --, a YoY change of 0.00%. Net income was -684.64K, a YoY change of 55.01%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Sales and Services Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Goods and Services | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gross Profit | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 340.05K -- | 132.71K -- | 145.82K -- | 206.43K -- | 180.92K -46.79% | 231.88K +74.73% | 229.79K +57.58% | 460.48K +123.07% | 689.50K +281.10% | 469.30K +102.39% | 1.22M +430.61% | 1.29M +179.51% | 3.15M +356.50% | 3.04M +547.74% | 2.08M +70.67% | 1.16M -9.87% | 903.54K -71.29% | 809.66K -73.37% | 951.02K -54.30% | 1.55M +34.05% | 1.04M +14.94% | 748.08K -7.61% | 715.27K -24.79% | 733.11K -52.85% | 3.23M -- |
Selling, General and Administrative Expenses | 172.95K -- | 123.71K -- | 2.95K -- | 184.74K -- | 135.42K -21.70% | 229.87K +85.81% | 229.79K +7700.03% | 425.95K +130.57% | 653.10K +382.26% | 451.70K +96.51% | 449.87K +95.77% | 531.21K +24.71% | 556.89K -14.73% | 744.62K +64.85% | 506.04K +12.49% | 712.93K +34.21% | 657.91K +18.14% | 459.22K -38.33% | 521.27K +3.01% | 450.37K -36.83% | 614.91K -6.54% | 556.47K +21.18% | 527.47K +1.19% | 475.91K +5.67% | 2.17M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | 484.34K -- | -- -- | -- -- | -- -- | 1.02M +110.81% | -- -- | -- -- | -- -- | 2.09M +104.29% | -- -- | -- -- | 506.04K -- | 712.93K -65.82% | 657.91K -- | 459.22K -- | 521.27K +3.01% | 450.37K -36.83% | 614.91K -6.54% | 556.47K +21.18% | 527.47K +1.19% | 475.91K +5.67% | 2.17M -- |
Research and Development Expenses | 167.10K -- | 9.00K -- | 142.88K -- | 21.69K -- | 45.50K -72.77% | 2.02K -77.60% | -- -- | 34.53K +59.16% | 36.40K -20.00% | 17.60K +773.02% | 769.41K -- | 755.89K +2089.20% | 2.59M +7017.16% | 2.30M +12941.20% | 1.57M +104.68% | 447.08K -40.85% | 245.63K -90.52% | 350.44K -84.73% | 429.75K -72.71% | 1.10M +147.07% | 423.58K +72.45% | 191.61K -45.32% | 187.81K -56.30% | 257.20K -76.72% | 1.06M -- |
Operating Income | -340.05K -- | -132.71K -- | -145.82K -- | -206.43K -- | -180.92K +46.79% | -231.88K -74.73% | -229.79K -57.58% | -460.48K -123.07% | -689.50K -281.10% | -469.30K -102.39% | -1.22M -430.61% | -1.29M -179.51% | -3.15M -356.50% | -3.04M -547.74% | -2.08M -70.67% | -1.16M +9.87% | -903.54K +71.29% | -809.66K +73.37% | -951.02K +54.30% | -1.55M -34.05% | -1.04M -14.94% | -748.08K +7.61% | -715.27K +24.79% | -733.11K +52.85% | -3.23M -- |
Non-Operating Income (Loss) | -255.25K -- | -247.32K -- | -248.23K -- | -247.28K -- | -250.82K +1.73% | -260.02K -5.13% | -279.51K -12.60% | 282.75K +214.34% | 0 +100.00% | 0 +100.00% | 0 +100.00% | 2.18M +671.21% | -562.36K -- | 1.27M -- | 161.18K -- | -389.88K -117.88% | 37.57K +106.68% | 25.93K -97.96% | 10.02K -93.78% | 33.22K +108.52% | 21.39K -43.05% | 7.56K -70.86% | 48.54K +384.45% | 48.46K +45.87% | 125.95K -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 2.91M -- | -- -- | -- -- | 160.65K -- | 24.76K -99.15% | 37.31K -- | 10.79K -- | -9.97K -106.21% | 12.96K -47.67% | 1.35K -96.37% | 902 -91.64% | 1.21K +112.15% | 498 -96.16% | 3.97K -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 297.50K -- | 0 -- | 0 -- | 0 -- | -731.71K -345.95% | -562.92K -- | 1.27M -- | -- -- | -414.99K +43.29% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | 255.25K -- | 247.32K -- | 248.23K -- | 247.28K -- | 250.82K -1.73% | 260.02K +5.13% | 279.51K +12.60% | 14.76K -94.03% | 0 -100.00% | 0 -100.00% | 0 -100.00% | 0 -100.00% | -556 -- | -428 -- | -536 -- | -349 -- | -255 +54.14% | -15.15K -3439.02% | -19.99K -3630.04% | -20.26K -5706.30% | -20.04K -7758.43% | -6.65K +56.07% | -47.33K -136.71% | -47.96K -136.70% | -121.98K -- |
Interest Expense | 255.25K -- | 247.32K -- | 248.23K -- | 247.28K -- | 250.82K -1.73% | 260.02K +5.13% | 279.51K +12.60% | 14.76K -94.03% | 0 -100.00% | 0 -100.00% | 0 -100.00% | 0 -100.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 556 -- | 428 -- | 536 -- | 349 -- | 255 -54.14% | 15.15K +3439.02% | 19.99K +3630.04% | 20.26K +5706.30% | 20.04K +7758.43% | 6.65K -56.07% | 47.33K +136.71% | 47.96K +136.70% | 121.98K -- |
Pretax Income From Continuing Operations | -595.30K -- | -380.03K -- | -394.05K -- | -453.71K -- | -431.75K +27.47% | -491.90K -29.44% | -509.30K -29.25% | -177.74K +60.83% | -689.50K -59.70% | -469.30K +4.59% | -1.22M -139.40% | 893.46K +602.69% | -3.71M -438.06% | -1.77M -276.99% | -1.92M -57.45% | -1.55M -273.47% | -865.97K +76.66% | -783.73K +55.70% | -941.00K +50.98% | -1.52M +1.82% | -1.02M -17.45% | -740.52K +5.51% | -666.74K +29.15% | -684.64K +55.01% | -3.11M -- |
Income Tax Expense | 1.60K -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -596.90K -- | -380.03K -- | -394.05K -- | -453.71K -- | -431.75K +27.67% | -491.90K -29.44% | -509.30K -29.25% | -177.74K +60.83% | -689.50K -59.70% | -469.30K +4.59% | -1.22M -139.40% | 893.46K +602.69% | -3.71M -438.06% | -1.77M -276.99% | -1.92M -57.45% | -1.55M -273.47% | -865.97K +76.66% | -783.73K +55.70% | -941.00K +50.98% | -1.52M +1.82% | -1.02M -17.45% | -740.52K +5.51% | -666.74K +29.15% | -684.64K +55.01% | -3.11M -- |
Net Income Attributable to Owners of the Company | -596.90K -- | -380.03K -- | -394.05K -- | -453.71K -- | -431.75K +27.67% | -491.90K -29.44% | -509.30K -29.25% | -177.74K +60.83% | -689.50K -59.70% | -469.30K +4.59% | -1.22M -139.40% | 893.46K +602.69% | -3.71M -438.06% | -1.77M -276.99% | -1.92M -57.45% | -1.55M -273.47% | -865.97K +76.66% | -783.73K +55.70% | -941.00K +50.98% | -1.52M +1.82% | -1.02M -17.45% | -740.52K +5.51% | -666.74K +29.15% | -684.64K +55.01% | -3.11M -- |
Other Adjustments | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 3.21M -- | 0 -- | -- -- | -- -- | 0 -100.00% | 0 -- | -- -- |
Net Income Attributable to Common Stockholders | -596.90K -- | -380.03K -- | -394.05K -- | -453.71K -- | -431.75K +27.67% | -491.90K -29.44% | -509.30K -29.25% | -177.74K +60.83% | -689.50K -59.70% | -469.30K +4.59% | -1.22M -139.40% | 893.46K +602.69% | -3.71M -438.06% | -1.77M -276.99% | -1.92M -57.45% | -1.55M -273.47% | -865.97K +76.66% | -783.73K +55.70% | -4.15M -116.36% | -1.52M +1.82% | -1.02M -17.45% | -740.52K +5.51% | -666.74K +83.95% | -684.64K +55.01% | -3.11M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -783.73K -- | -- -- | -- -- | -- -- | -740.52K +5.51% | -- -- | -- -- | -- -- |
Basic EPS | -0.08 -- | -0.05 -- | -0.14 -- | -- -- | -0.15 -87.50% | -0.17 -240.00% | -0.17 -21.43% | -0.02 -- | -0.07 +53.33% | -1.36 -700.00% | -3.53 -1976.47% | 0.06 +400.00% | -55.2 -78757.14% | -5.21 -283.09% | -4.9 -38.81% | -2.9 -4933.33% | -1.31 +97.63% | -4.02 +22.84% | -14.21 -190.00% | -0.52 +82.07% | -0.32 +75.57% | -1.33 +66.92% | -0.37 +97.40% | -0.38 +26.92% | -2.4 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -4.9 -- | -- -- | -1.31 -- | -4.02 -- | -14.21 -190.00% | -- -- | -0.32 +75.57% | -1.33 +66.92% | -0.37 +97.40% | -- -- | -- -- |
Diluted EPS | -0.08 -- | -0.05 -- | -0.14 -- | -- -- | -0.15 -87.50% | -0.17 -240.00% | -0.17 -21.43% | -- -- | -0.07 +53.33% | -1.36 -700.00% | -3.53 -1976.47% | -- -- | -55.2 -78757.14% | -5.21 -283.09% | -4.9 -38.81% | -- -- | -1.31 +97.63% | -4.02 +22.84% | -14.21 -190.00% | -- -- | -0.32 +75.57% | -1.33 +66.92% | -0.37 +97.40% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -4.9 -- | -- -- | -1.31 -- | -4.02 -- | -14.21 -190.00% | -- -- | -0.32 +75.57% | -1.33 +66.92% | -0.37 +97.40% | -- -- | -- -- |
You can ask Aime
What is the revenue and EPS growth rate for Bone Biologics year over year?What were the key takeaways from Bone Biologics's earnings call?What is the market's earnings forecast for Bone Biologics next quarter?What is Bone Biologics's gross profit margin?What factors drove the changes in Bone Biologics's revenue and profit?Did Bone Biologics beat or miss consensus estimates last quarter?What is Bone Biologics's latest dividend and current dividend yield?What guidance did Bone Biologics's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
